<DOC>
	<DOC>NCT02822547</DOC>
	<brief_summary>Patients will receive Peginterferon alfa-2a according to the standard medical practice but the observation period is 12 weeks</brief_summary>
	<brief_title>Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>History of HBsAg positive for more than 6 months HBeAgpositive or HBeAgnegative within 8 weeks Serum AST or ALT ≥ 80 IU/L HBeAg positive patients: Serum HBV DNA ≥ 1.0 X 10^5 copies/mL (or 20,000 IU/mL) HBeAgnegative patients: serum HBV DNA ≥ 1.0 X 10^4 copies/mL(or 2,000 IU/mL) History of antiviral therapy for Chronic hepatitis B within 6 months of study enrollment Prior treatment of interferon Presence of viral coinfections (hepatitis C, hepatitis delta, or human immunodeficiency virus) Other chronic liver disease or decompensated liver disease platelet&lt;90,000/mm3 or absolute neutrophil count &lt; 1,500 mm3 Pregnant or lactating woman History of Organ transplantation Treatment with immunosuppressive/immunomodulatory agents within 6 months prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>